Refractory Generalized Anxiety Disorder
J Clin Psychiatry 2009;70(suppl 2):32-38
© Copyright 2014 Physicians Postgraduate Press, Inc.
Access to this article is available to valid users
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Register: If you do not have one already, register for a free account.
Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.
Generalized anxiety disorder (GAD) has a lifetime prevalence in the US population of about 5.7%.
Typically, GAD begins in early adulthood and tends to have a chronic and persistent course. The disorder
frequently presents comorbidly with other conditions, and about 90% of patients with GAD
have at least 1 comorbid lifetime psychiatric disorder. Patients with GAD tend to be high users of
medical services; the disorder is associated with significant physical as well as psychological symptomatology
and impacts health, family relationships, and employment. Pharmacologic and psychosocial
treatments are available for GAD.